Atrion (Atrion) Debt-to-Asset

: 0.00 (As of Dec. 2023)

View and export this data going back to 1972. Start your Free Trial

Atrion's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil. Atrion's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil. Atrion's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $260.8 Mil. Atrion's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Atrion Debt-to-Asset Historical Data

The historical data trend for Atrion's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atrion Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

Atrion Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															-	-	0.01	0.02	-

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Atrion's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrion Debt-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Atrion's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Atrion's Debt-to-Asset falls into.

Atrion Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Atrion's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	260.825
	=	0.00

Atrion's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	260.825
	=	0.00

Atrion (NAS:ATRI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Atrion Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Atrion's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Atrion (Atrion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atrion Corp (NAS:ATRI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Allentown Parkway, Allen, TX, USA, 75002-4211

Website

https://www.atrioncorp.com

Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.

Executives

Preston G Athey	director	ONE ALLENTOWN PKWY, ALLEN TX 75002
David A Battat	officer: President & CEO	2700 HALKEY-ROBERTS PLACE NORTH, ST. PETERSBURG FL 33716-4103
Jeannette Bankes	director	ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Morgan Hugh J Jr	director
Ronald Nicholas Spaulding	director	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Cindy Ferguson	officer: Officer/ CFO	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffery Strickland	officer: Vice President & CFO
Emile A Battat	director, officer: Chairman	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Stupp John P Jr	director	STUPP JOHN P JR, #18 ST. ANDREWS DR., ST LOUIS MO 63124
Roger F Stebbing	director
Ronald N Spaulding	director	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Richard O Jacobson	director	ONE ALLENTOWN PARKWAY, C/O ATRION, ALLEN TX 75002
Maley John H P	director	6 ROCK CREST LANE, SIGNAL MOUNTAIN TN 37377
Margaret Maxwell Zagel	director	C/O TELLABS OPERATIONS INC, 4951 INDIANA AVE, LISLE IL 60532